Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,747.12 +379.52 (+0.56%) CMC Crypto 200
1,426.10 -2.47 (-0.17%)
INSM Aug 2024 25.000 put
| Previous close | 0.1000 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 25.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.1000 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 60 |
PR NewswireInsmed to Host Commercial Webinar on June 4, 2024
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP).
- PR Newswire
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $650 million. I
ZacksInsmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
